Figure 6From: Global analysis of ZNF217 chromatin occupancy in the breast cancer cell genome reveals an association with ERalphaHigh ZNF217 expression is enriched in ER + breast cancer. (A) Estrogen receptor status from Chin et al. 2006 study [36]. ZNF217 expression levels in primary tumors that were ER positive (n = 75) or ER negative (n = 43) compared by Mann–Whitney t-test (p = 0.009). (B) Estrogen receptor status from Hess et al. 2006 study [37]. ZNF217 expression levels in primary tumors that were ER-positive (n = 82) or negative (n = 51) and compared by Mann–Whitney t-test (p ≤ 0.001). (C) ZNF217 expression levels in patients separated by gene expression molecular subtypes (p = 0.0003; ANOVA,Kruskal-Wallis) from Chin et al. 2006 [36] study. (D) ZNF217 expression levels in patients separated by gene expression molecular subtypes (p = 0.0002; ANOVA,Kruskal-Wallis) from Hess et al. 2006 [37] study. For both analyses, individual cohort combinations were compared by Dunn’s multiple comparison test, and those marked with * had p < 0.05. Each line marks the mean for the subtype. (E) Immunoblotting of 15 breast tumor lysates with antibodies to ZNF217, ER, or actin as a loading control. ZNF217 and ER protein densitometry was quantitated (r2 = 0.93).Back to article page